SB683699

SB683699 · GlaxoSmithKline

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SB683699, covering 2015-04-13 to 2015-04-13. Get the full timeline:

Most recent: Clinical Trial Update: Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis [Phase 2]